Highlights

  • Group Revenue increased 3.6% to $2.99 million in 1HFY26.
  • Gross Margin improved to 44.3% compared with 41.9% in the prior corresponding period.
  • Supplement revenue increased 12.2% to $2.91 million.
  • Ovicoll progressed plans for a proposed ovine collagen Manufacturing Facility in Western Australia.

Holista Colltech Limited (ASX:HCT) reported continued progress across its health and wellness businesses during the half year ended 30 June 2026, with revenue growth supported by its Dietary Supplements division and ongoing product development activities.

Group revenue increased 3.6% to $2.99 million compared with $2.89 million in the prior corresponding period. Gross Profit increased to $1.33 million, while gross margin improved to 44.3% from 41.9%.

The company reported a net loss after tax of $2.56 million for the period, which included approximately $2.66 million in one-off costs associated with the ProImmune settlement matter. Excluding these costs, Holista reported an Underlying Profit after tax of approximately $95,000.

The Dietary Supplements division remained the largest contributor to revenue, generating sales of $2.91 million, up 12.2% year-on-year. The improvement was supported by the resolution of a legacy returns issue, a $128,000 favourable refund Liability adjustment and continued strengthening of the sales and Marketing team.

During the period, Holista expanded its marketplace presence through TikTok Shop and launched a refreshed E-commerce website to improve customer engagement.

Ovicoll Joint Venture Progresses Collagen Manufacturing Plans

Holista continued advancing its ovine collagen strategy through Ovicoll Pty Ltd, a 50:50 joint venture established with Swang Chai Chuan Limited.

During the period, SCC contributed RM5.0 million to Ovicoll, with the funds used to complete the Acquisition of land in Collie, Western Australia, for a proposed ovine collagen manufacturing facility.

Planning and implementation activities remain ongoing as the joint venture progresses development activities. Holista contributed intellectual property to Ovicoll, which had a nil carrying value in the company’s accounting records.

The Ovine Collagen division recorded revenue of $28,781 during the half year, reflecting the transition following the closure of the Collie facility. The company continues focusing on advancing future manufacturing capabilities through the joint venture structure.

Product Innovation and Financial Management Priorities

Holista’s Food Ingredients division recorded revenue of $29,963 during the period, compared with $204,889 in the prior corresponding period. The decline reflected changes in customer inventory management after the division’s main customer moved through a privatisation process.

The company is developing a new food ingredient formulation designed to support FDA-approved “sugar free” label claims with improved performance characteristics. This initiative is intended to broaden the division’s product offering and customer base.

The Infection Control and Agriculture division generated revenue of $23,484, with nano urea and poultry probiotic products progressing from trial runs towards more consistent repeat orders from agricultural customers.

The ProImmune matter was resolved during the period following settlement of the litigation for US$1.8 million. The final payment of US$800,000 was completed on 10 July 2026.

Holista continues focusing on consolidating recovery across its divisions through supplement growth, food ingredient innovation, collagen manufacturing plans and conversion of agriculture trials into repeat business.

Key Insights

Holista Colltech’s FY26 half year update highlighted revenue growth, improved gross margins and progress across its health and wellness portfolio. The company is focusing on supplement expansion, Ovicoll development, product innovation and operational management following resolution of the ProImmune matter.